Absci/$ABSI
1D1W1MYTD1Y5YMAX
Capital at risk
About Absci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
- Ticker
- $ABSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 140
- Headquarters
- Vancouver, United States
- Website
- www.absci.com
Absci Metrics
BasicAdvanced
$1.8B
-
-$0.80
2.44
-
Price and volume
Market cap
$1.8B
Beta
2.44
52-week high
$12.06
52-week low
$2.24
Average daily volume
3.4M
Financial strength
Current ratio
10.627
Quick ratio
10.263
Long term debt to equity
0.007
Total debt to equity
0.016
Interest coverage (TTM)
-1,389.36%
Profitability
EBITDA (TTM)
-119.506
Gross margin (TTM)
-5,395.64%
Net profit margin (TTM)
-7,756.37%
Operating margin (TTM)
-8,366.43%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-34.10%
Return on equity (TTM)
-57.72%
Valuation
Price to revenue (TTM)
1,038.596
Price to book
7.47
Price to tangible book (TTM)
8.92
Price to free cash flow (TTM)
-14.876
Free cash flow yield (TTM)
-6.72%
Free cash flow per share (TTM)
-0.72
Growth
Revenue change (TTM)
-62.28%
Earnings per share change (TTM)
-15.15%
3-year revenue growth (CAGR)
-43.30%
3-year earnings per share growth (CAGR)
-13.18%
What the Analysts think about Absci
Analyst ratings (Buy, Hold, Sell) for Absci stock.
Analyst projections of the future price of Absci stock.
Bulls say / Bears say
ABS-201’s early human data showed favourable tolerability across the reported single-ascending-dose cohorts, while its estimated half-life of at least 65 days could support only two or three injections over six months. That dosing profile could differentiate it from daily hair-loss treatments if efficacy is confirmed. (GlobeNewswire)
Eli Lilly invested $40 million in Absci’s $100 million offering and joined the endometriosis advisory board. The strategic involvement gives Absci added industry support as it advances ABS-201 in both hair loss and endometriosis. (Pharmaceutical Technology)
The June financing lifted cash, cash equivalents and marketable securities to $201.1 million, which Absci says should fund operations into the second half of 2028. That gives the company time to reach several important clinical catalysts without an immediate funding requirement. (Last10K)
The encouraging Phase 1 update covers blinded aggregate safety and pharmacokinetic data, not demonstrated hair-growth efficacy. The key proof-of-concept readouts are still due in the second half of 2026 and early 2027. (GlobeNewswire, Investing.com)
Absci remains heavily loss-making, with Q2 revenue of only $0.3 million against a $33.2 million net loss. Its cash runway therefore depends on continued spending discipline and the accuracy of management’s projections. (StockTitan)
ABS-201 may face a more advanced competitor: Hope Medicine’s anti-PRLR treatment HMI-115 is reported to be in Phase IIb/III and Phase III studies in China. That could make it harder for Absci to establish a first-mover advantage in hair loss. (Pharmaceutical Technology)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Absci Financial Performance
Revenues and expenses
Absci Earnings Performance
Company profitability
Upcoming events
No upcoming events
Absci News
AllArticlesVideos
Funds containing Absci
AllUSDEURGBP
Fund name | Fund size | $ABSI weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.15% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.15% |
iShares Healthcare Innovation£DRDR | £1B | 0.15% |
iShares Ageing Population€AGED | €822M | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.